Expression and clinical significance of erythroid progenitor cells in patients with sepsis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024887

Enrollment

Unknown

Registered

2019-08-02

Start date

2019-07-15

Completion date

Unknown

Last updated

2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Signed informed consent; 3. EICU patients diagnosed with sepsis or septic shock according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3); 4. Healthy volunteers are screened by the medical examination center.

Exclusion criteria

Exclusion criteria: 1. Treatment for no more than 24 hours of death or discharge; 2. Participate in other researchers at the same time; 3. Factors that may affect the accuracy of erythroid progenitor cells, such as acute blood loss, infusion of red blood cells and use of erythropoiesis drugs etc.

Design outcomes

Primary

Measure	Time frame
mHLA-DR;Erythroid progenitor cells;SOFA;APACHE-II;	—

Countries

China

Contacts

Public ContactZhongqiu Lu

The First Affiliated Hospital of Wenzhou Medical University

lzq640815@163.com+86 13957759958

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026